AstraZeneca’s Calquence plus chemoimmunotherapy approved in US for patients with previously untreated mantle cell lymphoma: Cambridge, UK Monday, January 20, 2025, 09:00 Hrs [IS ...

The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for ...

The new first-line MCL indication gives Calquence a slice of the market of its own and could spur further growth of the drug, ...

The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...

AstraZeneca's Calquence gains FDA approval for untreated mantle cell lymphoma, supported by data showing improved survival and reduced disease progression.

AstraZeneca (NASDAQ:AZN) announced Friday that the U.S. FDA approved its Bruton’s tyrosine kinase (BTK) inhibitor Calquence ...

WASHINGTON - The U.S. Food and Drug Administration has granted approval to AstraZeneca (NASDAQ:AZN)'s Calquence (acalabrutinib), in combination with bendamustine and rituximab, for the treatment of ...

The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...

Cambridge: AstraZeneca has announced that the Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) in ...

Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...

The Bruton tyrosine kinase inhibitor was approved in combination with bendamustine and rituximab in previously untreated ...

AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma ...